Lifemin (Lisdexamfetamine Dimesylate)

Lifemin (lisdexamfetamine dimesylate) is indicated for disorders within the attention‑deficit/hyperactivity disorder (ADHD) therapeutic area.

• Attention deficit hyperactivity disorder (children): Improves focus and reduces hyperactive behaviour in school‑aged patients.
• Attention deficit hyperactivity disorder (adolescents): Decreases impulsivity and supports academic performance during teenage years.
• Attention deficit hyperactivity disorder (adults): Enhances concentration and functional productivity in adult patients.

• Lisdexamfetamine dimesylate is a prodrug that is enzymatically converted to dextroamphetamine after oral absorption. The active dextroamphetamine increases the synaptic release of norepinephrine and dopamine while inhibiting their reuptake, thereby enhancing neurotransmission in brain regions that regulate attention, impulse control and activity levels.

Lifemin may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects

• Decreased appetite: Reduced hunger leading to weight loss.
• Insomnia: Difficulty falling or staying asleep.
• Dry mouth: Sensation of oral dryness.
• Headache: Mild to moderate cranial pain.
• Irritability: Mood changes and increased frustration.
• Nausea: Stomach upset or feeling sick.

Serious or Rare Side Effects

• Cardiovascular events: Elevated blood pressure or heart rate abnormalities.
• Psychiatric symptoms: New or worsening anxiety, depression, or psychosis.
• Growth suppression: Potential impact on height development in children.
• Seizures: Increased risk in susceptible individuals.
• Allergic reactions: Rash, swelling, or anaphylaxis.
• Peripheral vasculitis: Inflammation of small blood vessels.

Before prescribing Lifemin, clinicians should evaluate patient history and monitor for specific safety concerns.

• Cardiovascular assessment: Check blood pressure and heart rate baseline and periodically.
• Psychiatric evaluation: Screen for history of mood disorders, psychosis or substance misuse.
• Growth monitoring: Measure height and weight regularly in pediatric patients.
• Drug abuse potential: Consider risk of misuse due to stimulant properties.
• Pregnancy counseling: Discuss potential risks; category C indicates animal data show risk but benefits may outweigh.
• Store at ambient temperature: Keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Lifemin can interact with several medication classes, altering efficacy or safety.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): Risk of hypertensive crisis; avoid concurrent use.
• Tricyclic antidepressants: May increase cardiovascular side effects.
• Proton pump inhibitors (e.g., omeprazole): Can raise plasma levels of dextroamphetamine.

Moderate Interactions (Monitor Closely)

• Antihypertensives: May reduce blood‑pressure‑lowering effect.
• Antipsychotics: Potential for reduced stimulant efficacy.
• CYP2D6 inhibitors (e.g., fluoxetine): May modestly increase active metabolite exposure.